Publications
Atopic Dermatitis:
Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis. J Drugs Dermatol. 2018;17(7):750-756.
Hemophilia A:
Hereditary Angioedema:
Inherited Retinal Disease:
Zimmermann M, Lubinga SJ, Banken R, et al. Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease. Value Health. 2019;22(2):161-167.
Multiple Myeloma:
Carlson JJ, Guzauskas G, Chapman R, et al. Cost-effectiveness of drugs to treat relapsed/refractory Multiple Myeloma in the U.S. Journal of Managed Care and Specialty Pharmacy 2018 Jan;24(1):29-38
Carlson JJ, Guzauskas G, Chapman R, et al. Cost-effectiveness of drugs to treat relapse/refractory multiple myeloma in the US. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PCN107
Multiple Sclerosis:
Brouwer E, Carlson JJ, Zimmermann M. Drug-specific discontinuation rates for available multiple sclerosis treatments. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PND14
Strand L, Zimmermann M, Carlson JJ, Hansen RN. Cost-utility of early versus delayed treatment with interferon beta-1b in clinically isolated syndrom (CIS) from a United States (US) payer perspective. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PND33
Zimmermann M, Brouwer E, Tice JA, et al. Cost-utility of disease modifying therapies for relapsing-remitting multiple sclerosis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PND35
Non-alcoholic steatohepatitis (NASH):
Non-small Cell Lung Cancer:
Opioid Epidemic: Supervised Injection Facilities:
https://uwchoice.shinyapps.io/SIF-ICER-Dashboard/
Osteoporosis:
Prostate Cancer:
Psoriasis:
Hendrix N, Ollendorf DA, CHapman R, et al. Cost-effectiveness of targeted therapy for moderate-to-severe plaque psoriasis: an analysis based on an institute for clinical and economic review (ICER) report. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research; May 20-24, 2017; Boston, MA. PSS17
Type II Diabetes:
Ulcerative Colitis:
Final Evidence Report and Meeting Summary